Health Care Provider referrals to

Monoclonal Antibody Infusions



- Monoclonal antibodies (mAbs) directly neutralize the COVID-19 virus and are intended to prevent the progression of disease and reduce risk of hospitalization.
- mAbs are likely to be most beneficial if given to patients early in symptom progression (treatment) or ASAP after known or suspected exposure (post-exposure prophylaxis/PEP).
- Product is delivered via single IV infusion administration or under the skin (subcutaneous).

Process to refer your patients for treatment or PEP

1. Review patient eligibility criteria

Full criteria listed by FDA:

- Bamlanivimab and Etesevimab
- Casirivimab and Imdevimab
- <u>Sotrovimab</u>

2. Perform a COVID-19 PCR or Point-of-Care Rapid Antigen Test (for treatment only)

(POC Antigen Tests can be supplied by MDH; complete this <u>form</u> if interested).

3. Refer your positive patients or high-risk patients to a partnering infusion site ASAP

Start treatment within 10 days of onset of symptoms (treatment) or within 4 days of known or suspected exposure (PEP).

Option 1 (Preferred) OR Option 2

Send eReferral via the CRISP Unified Landing Page (<u>Starter guide</u>: pp. 1-7, 25-35) Complete <u>referral form</u> and submit directly to infusion site

(Link to proceed for all workflows)

There are dozens of mAb treatment facilities in Maryland. Providers refer based on location and availability. Locations can also be found through the <u>HHS website</u>.

Maryland sites accepting referrals

- Garrett Medical Center
- UPMC Western Maryland
- Meritus Medical Center
- UM Upper Chesapeake Health
- Hatzalah of Baltimore
- Baltimore Convention Center Field Hospital
- Odenton Volunteer Fire Department
- Anne Arundel Medical Center
- UMMS Capital Region Health-Laurel
- Adventist–Takoma Park
- Doctor's Community Hospital
- City of Praise Family Ministries
- Charles Regional Medical Center
- TidalHealth Peninsula Regional
- Atlantic General Hospital
- MedStar Harbor

Locations subject to change based on site capacity.

Health Care Provider referrals to

Monoclonal Antibody Infusions

Review full patient eligibility criteria

COVID-19 Treatment Eligibility Criteria

Adults and adolescents (12+) who weight at least 88 lbs and:

- Recently tested positive for COVID-19
- Are within 10 days of symptoms
- Do not need to be hospitalized
- Are or have one of the following:
 - o 65+
 - Overweight (BMI over 25)
 - Chronic kidney disease
 - Diabetes (Type 1 or Type 2)
 - Weakened immune system
 - Currently receiving immunosuppressive treatment
 - Cardiovascular disease/hypertension
 - Chronic lung disease
 - Sickle cell disease
 - Neurodevelopmental disorders
 - Medical-related technological dependence
 - Pregnant
 - Other significant conditions as determined by provider

Post-Exposure Prophylaxis Eligibility Criteria

Adults and adolescents (12+) who weight at least 88 lbs, have a high-risk medical condition. and:

- Had a known or suspected COVID-19 exposure in the past 4 days (96 hours)
- Are not fully vaccinated
- Are vaccinated but not expected to have an adequate immune response to the vaccine
- Are in a congregate living situation such as a nursing home or prison

Other Resources for Providers

Monoclonal Antibody Resources for Health Care Professionals

<u>FAQs About Monoclonal Antibodies for</u> <u>Consumers</u>

Crush COVID

